Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Author: 
Byrd, J.C. [etal]
Publisher: 
New England Journal of Medicine
Date published: 
2013
Record type: 
Journal Title: 
The New England Journal of Medicine
Source: 
The New England Journal of Medicine, Vol. 369, No. 1, July 4, 2013, pp. 32-42
Abstract: 

Ibrutinib inhibits Bruton's tyrosine kinase, a component of normal B-cell activation pathways. Ibrutinib produced responses in 71% of patients with refractory chronic lymphocytic leukemia.

Language: 

CITATION: Byrd, J.C. [etal]. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia . : New England Journal of Medicine , 2013. The New England Journal of Medicine, Vol. 369, No. 1, July 4, 2013, pp. 32-42 - Available at: https://library.au.int/targeting-btk-ibrutinib-relapsed-chronic-lymphocytic-leukemia-4